Page last updated: 2024-12-11
1,25-dihydroxy-19-norvitamin d3
Description
## 1,25-Dihydroxy-19-norvitamin D3: A Synthetic Vitamin D Analogue
1,25-Dihydroxy-19-norvitamin D3 (also known as **calcipotriol**) is a **synthetic vitamin D analogue**. It's a powerful drug with several important properties, making it a subject of extensive research.
**Here's a breakdown of its characteristics and importance in research:**
* **Structure:** 1,25-Dihydroxy-19-norvitamin D3 is structurally similar to the natural hormone **1,25-dihydroxyvitamin D3 (calcitriol)**, which is the active form of vitamin D in the body. However, it differs in the absence of a carbon atom at position 19 in its molecular structure.
* **Mechanism of Action:** Like calcitriol, it binds to the **vitamin D receptor (VDR)**, which is a nuclear receptor present in various cells throughout the body. This binding triggers the activation of specific genes and pathways, leading to a variety of biological effects.
* **Pharmacological Properties:**
* **Potent anti-proliferative activity:** It inhibits cell growth and proliferation, particularly in cells involved in **psoriasis** and other skin disorders.
* **Immunomodulatory effects:** It can modulate the immune system, suppressing inflammation and promoting immune tolerance.
* **Anti-inflammatory effects:** It reduces inflammation by inhibiting the production of pro-inflammatory cytokines.
* **Therapeutic Applications:**
* **Psoriasis treatment:** It's a widely used topical treatment for psoriasis, effectively reducing skin scaling, redness, and inflammation.
* **Other dermatological conditions:** It is also being investigated for the treatment of other skin diseases like acne, vitiligo, and alopecia areata.
* **Cancer research:** Its anti-proliferative properties make it a potential therapeutic agent for various cancers.
* **Immunomodulation:** Its immunomodulatory effects are being explored in autoimmune diseases like multiple sclerosis and rheumatoid arthritis.
**Why is it important for research?**
1. **Improved efficacy and safety:** Researchers continue to investigate the optimal use of 1,25-dihydroxy-19-norvitamin D3, seeking to improve its efficacy, minimize side effects, and develop novel formulations for better delivery and targeted action.
2. **New therapeutic applications:** The unique properties of this synthetic analogue offer exciting opportunities for its use in treating a wider range of diseases beyond psoriasis.
3. **Understanding vitamin D signaling:** Studies with this analogue help researchers unravel the intricate mechanisms of vitamin D signaling and its diverse effects on the body.
4. **Drug development:** 1,25-dihydroxy-19-norvitamin D3 serves as a lead compound for developing newer, more potent and targeted vitamin D analogues with improved pharmacological profiles.
**In conclusion**, 1,25-dihydroxy-19-norvitamin D3 is a powerful synthetic analogue with significant therapeutic potential, making it an active area of research in dermatology, immunology, and oncology. Its investigation holds promise for developing novel treatments and gaining a deeper understanding of vitamin D's role in human health.
1,25-dihydroxy-19-norvitamin D3: RN refers to (1alpha,3beta,7E)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 9547326 |
CHEMBL ID | 119386 |
SCHEMBL ID | 12047912 |
MeSH ID | M0222385 |
Synonyms (19)
Synonym |
1alpha,25-dihydroxy-19-norvitamin d3 / 1alpha,25-dihydroxy-19-norcholecalciferol |
(7e)-(1r,3r)-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol |
LMST03020074 , |
CHEMBL119386 |
1,25-dihydroxy-19-norvitamin d3 |
130447-37-9 |
20-epi-19-nor-1,25-(oh)2 d3 |
1alpha,25-(oh)2-19-nor-vitamin d3 |
1,3-cis-25-dihydroxy-19-norvitamin d3 |
19-nor-22(e) |
19-nor-9,10-secocholesta-5,7-diene-1,3,25-triol, (1alpha,3beta,7e)- |
k5zm856psa , |
unii-k5zm856psa |
SCHEMBL12047912 |
19-nor-vitamin d |
1,3-cyclohexanediol, 5-((2e)-2-((1r,3as,7ar)-octahydro-1-((1r)-5-hydroxy-1,5-dimethylhexyl)-7a-methyl-4h-inden-4-ylidene)ethylidene)-, (1r,3s)- |
19-nor-1.alpha.,25-dihydroxyvitamin d3 |
PKFBWEUIKKCWEW-WEZTXPJVSA-N |
(1r,3r)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol |
Research Excerpts
Bioavailability
Bioassays (4)
Assay ID | Title | Year | Journal | Article |
AID81829 | In vitro induction of cell differentiation in HL-60 cells relative to 1,25(OH)2D3 (100) | 1999 | Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
| Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20. |
AID216845 | Binding affinity for human vitamin D binding protein (hDBP) relative to 1,25(OH)2D3 (100) | 1999 | Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
| Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20. |
AID217011 | Binding affinity for porcine intestinal Vitamin D3 receptor (VDR) relative to 1,25(OH)2D3 (100) | 1999 | Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
| Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20. |
AID110582 | Hypercalcemic effect by daily sc injection of compound was measured as serum calcium concentration in vitamin D-replete normal NMRI mice relative to 1,25(OH)2D3 (100) | 1999 | Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
| Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (27)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (22.22) | 18.2507 |
2000's | 15 (55.56) | 29.6817 |
2010's | 6 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.02
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.02 (24.57) | Research Supply Index | 3.40 (2.92) | Research Growth Index | 4.42 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (3.45%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 28 (96.55%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |